Mr. Gu practiced law with Covington & Burling LLP in Shanghai, Washington D.C., and New York for approximately eight years before joining Han Kun Law Offices in 2022. Prior to Covington, Mr. Gu also interned and worked for many years in the New York office of Jun He Law Offices and the Shanghai office of Advokatfirman Vinge KB.
Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities. Specifically, Mr. Gu's services cover a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has been interviewed by Blue View, Caixin, China Business Network, Dutch Financial Daily, Faxian Magazine, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Thomson Reuters and other media (in alphabetical order).
Mr. Gu has extensive experience representing different types of companies in the life sciences industries, including but not limited to multinational pharmaceutical companies such as Abbott, AbbVie, Amgen, Astellas, AstraZeneca, BioNTech, bioMérieux, Eli Lilly, GlaxoSmithKline, Illumina, Johnson & Johnson, Merck, Merck Sharp & Dohme, Sanofi, and Viatris, biotech companies such as BeiGene, Connect Biopharma, Henlius, Huadong Medicine, Innovent, Legend Biotech, WuXi Biologics and Zai Lab, leading Internet companies such as Baidu, Tencent and ByteDance as well as investment institutions such as C Capital, CBC Group, IDG Capital, Matrix Partners, OrbiMed, Qiming Venture Partners, Sequoia Capital and Tiantu Capital (in alphabetical order).
